Anthem (NASDAQ:ANTX) Posts Quarterly Earnings Results

Anthem (NASDAQ:ANTX) posted its quarterly earnings results on Monday. The company reported ($0.17) EPS for the quarter, FiscalAI reports.

Here are the key takeaways from Anthem’s conference call:

• AN2 received FDA clearance to begin its Phase II polycythemia vera (PV) trial and expects to dose the first patient this year. The 75-patient study will test three doses; initial sentinel-cohort safety data are expected in Q1, with broader efficacy updates potentially starting around mid-2027. The drug has a substantial prior safety and hematocrit-effect database, but has not yet been tested in PV patients.
• The company expects to start a 60-patient, two-dose Phase II Chagas study in Bolivia in early 2027, with a readout targeted for the second half of the year. AN2 cited positive monkey studies and the potential for a priority review voucher if successful, while emphasizing the disease’s unmet need and an estimated 300,000-plus U.S. cases.
• AN2 is advancing epetraborole for M. abscessus lung disease, where it says an oral treatment could improve on prolonged IV antibiotic regimens and its preclinical profile supports testing in treatment-naive patients. This program follows the company’s Phase III miss in treatment-refractory MAC; management attributed that result to a particularly difficult patient population, but the new program’s clinical efficacy remains unproven.
• Management described a broad early-stage pipeline, including a hypophosphatasia program expected to enter Phase I next year and preclinical oncology programs such as a pan-mutant PI3K inhibitor. The PI3K program remains in research, and AN2 said it is still seeking a suitable compound before developing it further or pursuing a strategic partner.

Anthem Price Performance

NASDAQ:ANTX traded up $0.35 during trading hours on Wednesday, hitting $4.68. The company had a trading volume of 50,187 shares, compared to its average volume of 590,901. The stock has a 50-day moving average price of $4.69 and a 200 day moving average price of $4.14. The company has a market capitalization of $176.66 million, a PE ratio of -5.05 and a beta of -0.93. Anthem has a 52 week low of $1.00 and a 52 week high of $7.19.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ANTX shares. Guggenheim began coverage on shares of Anthem in a report on Monday, July 20th. They issued a “buy” rating and a $9.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anthem in a report on Friday, October 2nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Anthem has a consensus rating of “Hold” and an average price target of $9.00.

Insider Buying and Selling

In other news, Director Robin Shane Readnour sold 35,402 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $6.01, for a total value of $212,766.02. Following the completion of the sale, the director directly owned 565,592 shares of the company’s stock, valued at approximately $3,399,207.92. This trade represents a 5.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 55,727 shares of company stock valued at $330,207. 22.61% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Anthem

Institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its holdings in Anthem by 10,422.0% in the third quarter. Russell Investments Group Ltd. now owns 222,225 shares of the company’s stock worth $1,182,000 after buying an additional 220,113 shares during the period. Seven Fleet Capital Management LP grew its holdings in shares of Anthem by 4.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 208,946 shares of the company’s stock worth $1,011,000 after acquiring an additional 9,245 shares during the period. Velan Capital Investment Management LP purchased a new position in shares of Anthem during the 2nd quarter worth approximately $194,000. Citizens Financial Group Inc. RI purchased a new position in shares of Anthem during the 2nd quarter worth approximately $1,443,000. Finally, Vivo Capital LLC bought a new position in shares of Anthem in the 1st quarter worth approximately $10,785,000. 90.47% of the stock is owned by institutional investors.

Anthem Company Profile

An2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM). Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs.